ArticlePharmaceutics2021
Development of [
Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 55 citations in OpenAlex.
- Proof-of-Concept of CAIX-Targeted α-Particle Delivery in a Patient-Derived Hypoxic Head and Neck Squamous Cell Carcinoma Model.Molecular imaging and biology · 2026Article
- [International journal of molecular sciences · 2026Article
- Toward Personalized Theranostics: A Modular PET Platform for Antibody-Based Imaging and Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Inline gamma spectroscopy and liquid scintillation HPLC reveal daughters inEJNMMI radiopharmacy and chemistry · 2026Article
- Radiochemistry and comparative in vitro assessment of PSMA-617 labeled with lead-212 (EJNMMI radiopharmacy and chemistry · 2026Article
- Alpha Therapy Beyond TOC and TATE-Production, Quality Control, and In-Human Results for the SSTR2 Antagonist DOTA-LM3.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Quality control of actinium-225 andEJNMMI radiopharmacy and chemistry · 2026Article
- Assessment of quality control and effect of radiolysis on the in vivo biodistribution of [EJNMMI radiopharmacy and chemistry · 2025Article
- [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Evaluation of relative biological effectiveness ofEJNMMI physics · 2025Article
- Ac-225 radiochemistry through the lens of [EJNMMI radiopharmacy and chemistry · 2025Article
- Improvement of End-of-Synthesis Radiochemical Purity ofPharmaceutics · 2024Article
- Optimization Processes of Clinical Chelation-Based Radiopharmaceuticals for Pathway-Directed Targeted Radionuclide Therapy in Oncology.Pharmaceutics · 2024Review
- Imaging and therapy in prostate cancer using prostate specific membrane antigen radioligands.The British journal of radiology · 2024Review
- Design ofAnnals of translational medicine · 2024Review
- Review
- Implementing Ac-225 labelled radiopharmaceuticals: practical considerations and (pre-)clinical perspectives.EJNMMI radiopharmacy and chemistry · 2024Review
- Targeted Alpha Therapy: All We Need to Know aboutPharmaceuticals (Basel, Switzerland) · 2023Review
- Alpha Particle-Emitting Radiopharmaceuticals as Cancer Therapy: Biological Basis, Current Status, and Future Outlook for Therapeutics Discovery.Molecular imaging and biology · 2023Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 3 countries.
Funding
Abstract
Recently, promising results of the antitumor effects were observed in patients with metastatic castration-resistant prostate cancer treated with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.